Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non–Small-Cell Lung Cancer?

by Kulkarni, Amit A., Naqash, Abdul Rafeh, Puri, Sonam, Dienstmann, Rodrigo
Published in JCO Precis Oncol (2021)

The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

by Mittra, Arjun, Takebe, Naoko, Florou, Vaia, Chen, Alice P, Naqash, Abdul Rafeh
Published in Hum Vaccin Immunother (2020)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

by Macherla, Shravanti, Laks, Shachar, Naqash, Abdul Rafeh, Bulumulle, Anushi, Zervos, Emmanuel, Muzaffar, Mahvish
Published in Int J Mol Sci (2018)

Epigenetics: A primer for clinicians

by Paluch, Benjamin E, Naqash, Abdul Rafeh, Brumberger, Zachary, Nemeth, Michael J., Griffiths, Elizabeth A.
Published in Blood Rev (2016)

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome

by Hafiz, Maida, Sundaram, Suneha, Naqash, Abdul Rafeh, Speicher, James, Sutton, Ann, Walker, Paul, Talaat, Nizar
Published in ACG Case Rep J (2019)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer

by Naqash, Abdul Rafeh, Kihn-Alarcón, Alba J., Stavraka, Chara, Kerrigan, Kathleen, Maleki Vareki, Saman, Pinato, David James, Puri, Sonam
Published in Ann Transl Med (2021)

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-in...

by Naqash, Abdul Rafeh, File, Danielle M., Ziemer, Carolyn M., Whang, Young E., Landman, Paula, Googe, Paul B., Collichio, Frances A.
Published in J Immunother Cancer (2019)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

by Naqash, Abdul Rafeh, Appah, Ebenezer, Yang, Li V., Muzaffar, Mahvish, Marie, Mona A., Mccallen, Justin D., Macherla, Shravanti, Liles, Darla, Walker, Paul R.
Published in J Immunother Cancer (2019)

Co-relation of Overall Survival with Peripheral Blood-Based Inflammatory Biomarkers in Advanced Stage Non-Small Cell Lung Cancer Treated with Anti-Programmed Cell Death-1 Therapy:...

by Naqash, Abdul Rafeh, Stroud, Chipman Robert Geoffrey, Butt, Muhammad Umer, Hegde, Aparna, Dy, Grace K., Muzaffar, Mahvish, Yang, Li V., Cherry, Cynthia R., Hafiz, Maida, Walker, Paul R.
Published in Acta Oncol (2017)

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

by Shankar, Bairavi, Zhang, Jiajia, Naqash, Abdul Rafeh, Forde, Patrick M., Feliciano, Josephine L., Marrone, Kristen A., Ettinger, David S., Hann, Christine L., Brahmer, Julie R., Ricciuti, Biagio, Owen, Dwight, Toi, Yukihiro, Walker, Paul, Otterson, Gregory A., Patel, Sandip H., Sugawara, Shunichi, Naidoo, Jarushka
Published in JAMA Oncol (2020)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

by Abu-Sbeih, Hamzah, Ali, Faisal S., Naqash, Abdul Rafeh, Owen, Dwight H., Patel, Sandipkumar, Otterson, Gregory A., Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K., Wang, Yinghong
Published in J Clin Oncol (2019)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

by Pinato, David J., Kaneko, Takahiro, Saeed, Anwaar, Pressiani, Tiziana, Kaseb, Ahmed, Wang, Yinghong, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Naqash, Abdul Rafeh, Muzaffar, Mahvish, Navaid, Musharraf, Lee, Chieh-Ju, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Nimkar, Neil, Bettinger, Dominik, Hildebrand, Hannah, Abugabal, Yehia I., Ang, Celina, Marron, Thomas U., Khan, Uqba, Personeni, Nicola, Rimassa, Lorenza, Huang, Yi-Hsiang
Published in Cancers (Basel) (2020)

Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

by Takebe, Naoko, Naqash, Abdul Rafeh, Coyne, Geraldine O’Sullivan, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B., Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H., Chen, Alice P.
Published in Clin Cancer Res (2021)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

by Pinato, David J, Kaseb, Ahmed, Wang, Yinghong, Saeed, Anwaar, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Naqash, Abdul Rafeh, Muzaffar, Mahvish, Navaid, Musharraf, Khan, Uqba, Lee, ChiehJu, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Fessas, Petros, Nimkar, Neil, Bettinger, Dominik, Hildebrand, Hannah, Pressiani, Tiziana, Abugabal, Yehia I, Personeni, Nicola, Huang, Yi-Hsiang, Lozano-Kuehne, Jingky, Rimassa, Lorenza, Ang, Celina, Marron, Thomas U
Published in J Immunother Cancer (2020)

Considerations for treatment duration in responders to immune checkpoint inhibitors

by Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G, Olson, Daniel, Naqash, Abdul Rafeh, Patel, Ravi B, Sachdev, Esha, Rodriguez-Ruiz, Maria E, Sheffer, Michal, Church, Sarah, Fuhrman, Christopher, Overacre-Delgoffe, Abigail, Nguyen, Rosa, Florou, Vaia, Thaxton, Jessica E, Aggen, David H, Guerriero, Jennifer L
Published in J Immunother Cancer (2021)